ReNerve has never been listed on the ASX.
Its had a few earlier funding rounds to get it to this stage.
Compares well to Orthocell (OCC) with a market cap of $135 mil.
ReNerve will have an EV of $20 mil and is arguably further advanced than Orthocell.
Dr Julian Chick is the MD and he is also a Director of LTP which has been massively successful as an IPO.
I suspect that investors will be hoping for more of the same here.
Looking good.
Add to My Watchlist
What is My Watchlist?
